Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure. Cinaciguat has potent preload- and afterload-reducing effects, increasing cardiac output. Cinaciguat causes potent and sustained fetal pulmonary vasodilation that is augmented in the presence of oxidized sGC and speculate that Cinaciguat may have therapeutic potential for severe neonatal pulmonary hypertension.

June 21, 2017

prudect name : Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure. Cinaciguat has potent preload- and afterload-reducing effects, increasing cardiac output. Cinaciguat causes potent and sustained fetal pulmonary vasodilation that is augmented in the presence of oxidized sGC and speculate that Cinaciguat may have therapeutic potential for severe neonatal pulmonary hypertension.
Cinaciguat BAY-58-2667

Synonyms: Cinaciguat BAY-58-2667CAS NO: 329773-35-5Molecular Formula: C₃₆H₃₉NO₅Molecular Weight: 565.7Purity: 98% minSolubility: In DMSOStorage: -20°C

BAY41-2272 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18506053